KROS logo

Keros Therapeutics (KROS) Cash From Operations

Annual CFO

-$160.87 M
-$36.36 M-29.20%

December 31, 2024


Summary


Performance

KROS Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherKROScash flowmetrics:

Quarterly CFO

-$46.01 M
-$15.51 M-50.85%

December 31, 2024


Summary


Performance

KROS Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherKROScash flowmetrics:

TTM CFO

-$160.87 M
-$20.55 M-14.64%

December 31, 2024


Summary


Performance

KROS TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherKROScash flowmetrics:

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

KROS Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-29.2%0.0%0.0%
3 y3 years-158.8%-135.2%-158.8%
5 y5 years-905.6%-736.8%-905.6%

KROS Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-158.8%at low-3124.1%at low-203.1%at low
5 y5-year-905.6%at low-3124.1%at low-905.6%at low
alltimeall time-2384.4%at low-3124.1%at low-6301.5%at low

Keros Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Dec 2024
-$160.87 M(+29.2%)
-$46.01 M(+50.8%)
-$160.87 M(+14.6%)
Sep 2024
-
-$30.50 M(-23.4%)
-$140.32 M(-2.4%)
Jun 2024
-
-$39.80 M(-10.7%)
-$143.80 M(+6.7%)
Mar 2024
-
-$44.56 M(+75.0%)
-$134.83 M(+8.3%)
Dec 2023
-$124.51 M(+77.7%)
-$25.46 M(-25.1%)
-$124.51 M(+3.3%)
Sep 2023
-
-$33.98 M(+10.2%)
-$120.49 M(+8.4%)
Jun 2023
-
-$30.83 M(-9.9%)
-$111.11 M(+8.0%)
Mar 2023
-
-$34.23 M(+59.7%)
-$102.87 M(+46.8%)
Dec 2022
-$70.06 M(+12.7%)
-$21.44 M(-12.8%)
-$70.06 M(+2.8%)
Sep 2022
-
-$24.60 M(+8.9%)
-$68.18 M(+17.5%)
Jun 2022
-
-$22.59 M(+1483.0%)
-$58.02 M(+9.3%)
Mar 2022
-
-$1.43 M(-92.7%)
-$53.07 M(-14.6%)
DateAnnualQuarterlyTTM
Dec 2021
-$62.15 M(+68.5%)
-$19.57 M(+35.5%)
-$62.15 M(+22.9%)
Sep 2021
-
-$14.44 M(-18.1%)
-$50.57 M(+7.6%)
Jun 2021
-
-$17.64 M(+67.9%)
-$46.99 M(+19.6%)
Mar 2021
-
-$10.51 M(+31.5%)
-$39.28 M(+6.5%)
Dec 2020
-$36.89 M(+130.6%)
-$7.99 M(-26.4%)
-$36.89 M(+7.2%)
Sep 2020
-
-$10.86 M(+9.4%)
-$34.40 M(+29.8%)
Jun 2020
-
-$9.93 M(+22.3%)
-$26.50 M(+22.7%)
Mar 2020
-
-$8.12 M(+47.7%)
-$21.61 M(+35.0%)
Dec 2019
-$16.00 M(-327.2%)
-$5.50 M(+86.1%)
-$16.00 M(+52.4%)
Sep 2019
-
-$2.96 M(-41.3%)
-$10.50 M(+39.2%)
Jun 2019
-
-$5.03 M(+100.2%)
-$7.54 M(+200.2%)
Mar 2019
-
-$2.51 M
-$2.51 M
Dec 2018
$7.04 M
-
-

FAQ

  • What is Keros Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Keros Therapeutics?
  • What is Keros Therapeutics annual CFO year-on-year change?
  • What is Keros Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Keros Therapeutics?
  • What is Keros Therapeutics quarterly CFO year-on-year change?
  • What is Keros Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Keros Therapeutics?
  • What is Keros Therapeutics TTM CFO year-on-year change?

What is Keros Therapeutics annual cash flow from operations?

The current annual CFO of KROS is -$160.87 M

What is the all time high annual CFO for Keros Therapeutics?

Keros Therapeutics all-time high annual cash flow from operations is $7.04 M

What is Keros Therapeutics annual CFO year-on-year change?

Over the past year, KROS annual cash flow from operations has changed by -$36.36 M (-29.20%)

What is Keros Therapeutics quarterly cash flow from operations?

The current quarterly CFO of KROS is -$46.01 M

What is the all time high quarterly CFO for Keros Therapeutics?

Keros Therapeutics all-time high quarterly cash flow from operations is -$1.43 M

What is Keros Therapeutics quarterly CFO year-on-year change?

Over the past year, KROS quarterly cash flow from operations has changed by $0.00 (0.00%)

What is Keros Therapeutics TTM cash flow from operations?

The current TTM CFO of KROS is -$160.87 M

What is the all time high TTM CFO for Keros Therapeutics?

Keros Therapeutics all-time high TTM cash flow from operations is -$2.51 M

What is Keros Therapeutics TTM CFO year-on-year change?

Over the past year, KROS TTM cash flow from operations has changed by $0.00 (0.00%)